17226788

Source:http://linkedlifedata.com/resource/pubmed/id/17226788

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0022877, umls-concept:C0030705, umls-concept:C1257975, umls-concept:C1519814
pubmed:issue	1
pubmed:dateCreated	2007-2-5
pubmed:abstractText	Mesenchymal Stem Cells (MSCs) are non-hematopoietic multi-potent stem-like cells that are capable of differentiating into both mesenchymal and non-mesenchymal lineages. In fact, in addition to bone, cartilage, fat, and myoblasts, it has been demonstrated that MSCs are capable of differentiating into neurons and astrocytes in vitro and in vivo. MSCs are of interest because they are isolated from a small aspirate of bone marrow and can be easily expanded in vitro. As such, these cells are currently being tested for their potential use in cell and gene therapy for a number of human diseases. Nevertheless, there are still some open questions about origin, multipotentiality, and anatomical localization of MSCs. In this review, we discuss clinical trials based on the use of MSCs in cardiovascular diseases, such as treatment of acute myocardial infarction, endstage ischemic heart disease, or prevention of vascular restenosis through stem cell-mediated injury repair. We analyze data from clinical trials for treatment of osteogenesis imperfecta (OI), which is a genetic disease characterized by production of defective type I collagen. We describe progress for neurological disease treatment with MSC transplants. We discuss data on amyotrophic lateral sclerosis (ALS) and on lysosomal storage diseases (Hurler syndrome and metachromatic leukodystrophy). A section of review is dedicated to ongoing clinical trials, involving MSCs in treatment of steroid refractory Graft Versus Host Disease (GVHD); periodontitis, which is a chronic disease affecting periodontium and causing destruction of attachment apparatus, heart failure, and bone fractures. Finally, we will provide information about biotech companies developing MSC therapy.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0050222
pubmed:citationSubset	IM
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0021-9541
pubmed:author	pubmed-author:GalderisiUmbertoU, pubmed-author:GiordanoAntonioA, pubmed-author:MarinoIgnazio RIR
pubmed:copyrightInfo	(c) 2007 Wiley-Liss, Inc.
pubmed:issnType	Print
pubmed:volume	211
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	27-35
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:17226788-Bone Marrow Cells, pubmed-meshheading:17226788-Clinical Trials as Topic, pubmed-meshheading:17226788-Humans, pubmed-meshheading:17226788-Mesenchymal Stem Cell Transplantation, pubmed-meshheading:17226788-Mesenchymal Stem Cells, pubmed-meshheading:17226788-Tissue Therapy
pubmed:year	2007
pubmed:articleTitle	From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells.
pubmed:affiliation	Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, Pennsylvania, USA. giordano@temple.edu
pubmed:publicationType	Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural